Shear Wave Elastography Technology to Evaluate the Efficacy of ESW in the Treatment of Patients With Chronic Plantar Fasciitis
Not Applicable
- Conditions
- Chronic Plantar Fasciitis
- Interventions
- Device: Focused shockwaveOther: Home therapy
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT05032300
- Locations
- 🇨🇳
Nanfang Hospital ,Southern Medical University, Guangzhou, Guangdong, China
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
- Conditions
- Inflammatory ResponseARDS
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 560
- Registration Number
- NCT05020210
- Locations
- 🇨🇳
Southern medical university Nanfang hospital, Guangzhou, China
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 39
- Registration Number
- NCT05003700
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells
- Conditions
- Chronic Myeloid Leukemia
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 324
- Registration Number
- NCT04991532
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Effects of Ulinastatin on Inflammatory Response During ECMO Support
- Conditions
- Inflammatory ResponseECMO
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 144
- Registration Number
- NCT04990752
- Locations
- 🇨🇳
Nangfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Time Restricted Feeding on Nonalcoholic Fatty Liver Disease ( TREATY-FLD )：a 12-month Follow-up Study
Not Applicable
Completed
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Behavioral: Continuous Energy RestrictionBehavioral: Time restricted feeding
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 88
- Registration Number
- NCT04988230
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation
Phase 3
Not yet recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: Zebutinib&BR or Zebutinib&FCR
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 45
- Registration Number
- NCT04980859
Dynamic Changes of the Human Microbiome Predict the Risk of Poor Prognosis in Patients With Acute Ischemic Stroke: a Multi-center Study
Recruiting
- Conditions
- Acute Ischemic Stroke
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 2000
- Registration Number
- NCT04978701
- Locations
- 🇨🇳
Department of Neurology, NanFang Hospital, Southern Medical University, Guanzhou, Guangdong, China
Research on the Application and Mechanism of New Biological Probes in Biomedicine
Completed
- Conditions
- TumorsMetabolic DiseasesImmune System DiseasesEndocrine System DiseasesBlood DiseasesCardiovascular DiseasesUrinary System DiseasesInfectious DiseasesRespiratory System DiseasesDigestive System Diseases
- Interventions
- Diagnostic Test: No intervention
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 737
- Registration Number
- NCT04977739
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: Carelizumab Combined With Irinotecan and Apatinib
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 85
- Registration Number
- NCT04934618
- Locations
- 🇨🇳
NanFang Hospital, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath